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The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is
independent of prognosis and is not associated with mutated N- or K-ras
alleles in human bone marrow aspirates
BC Millar, JBG Bell, R Barfoot and M Everard
Section ofAcademic Haematologv. The McElwain Laboratories, Institute ofCancer Research, Sutton, Surrey. U'K.
Sumnuary During the period September 1987 to March 1993 the proliferation of myeloma cells as colonies
(MY-CFUc) in vitro was exaamined in bone marrow aspirates from 43 patients with multiple myeloma and two
patients with Waldenstr6m's macroglobulinaemia. Twenty-four samples from 45 patients. of whom three were
at presentation. four were in complete remission (CR). six had achieved a partial response (PR) and II had
progressive disease (PD), produced MY-CFUc in vitro. The same bone marrow aspirates or one taken within 2
months of that assessed for MY-CFUc were used in the polymerase chain reaction (PCR). Genomic DNA was
analysed for mutations in N- and K-ras by slot blotting of the amplified products from the PCR with
3P-labelled probes and by direct sequencing. No mutations were detected in N- or K-ras proto-oncogenes at
codons 12. 13 or 61 in any sample. Eleven of the patients from whom MY-CFUc were produced remain alive
with a median survival of 73 months (range 15-75 months). MY-CFUc have been cultured from 19 of these
24 patients on subsequent occasions, of whom nine remain alive. Among patients whose cells did not produce
MY-CFUc in vitro at the time of sampling for mutated ras alleles, biopsy samples from four patients have
produced MY-CFUc in vitro on subsequent occasions, of whom one patient remains alive. The data show that
the proliferation of MY-CFUc in vitro occurred independently of disease status and was not indicative of
prognosis. The failure to detect mutated N- or K-ras alleles in any sample suggests that if such mutations were
present in the cells which form colonies in vitro they represented less than 0.100 of the tumour burden and did
not affect the survival of this group of patients.
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During the past 8 years we have had some success in cultur-
mg multiple myeloma as colonies (MY-CFUc) in vitro from
human bone marrow aspirates (Millar et al., 1988). Although
MY-CFUc can be cultured from approximately 70% of
patients at some time during treatment, in remission and/or
at relapse the likelihood of growing the tumour in vitro is
dependent on the individual patient and cannot be predicted
from the level of bone marrow infiltration with plasma cells
(Bell et al., 1990; Maitland et al., 1990). Furthermore, the
growth of MY-CFUc is not necessarily associated with pro-
gressive or fulminating disease (Bell et al., 1990; Maitland et
al., 1990). Since there are a number of patients from whom it
has not been possible to grow MY-CFUc in vitro at any
stage of disease, there is clearly scope for refining the culture
procedure or determining whether there are specific genetic
mutations in some myeloma cell populations which facilitate
tumour cell proliferation in vitro in the absence of added
growth factors. However, the significance of such mutations
will only be of clinical value if their presence is associated not
only with proliferative activity in vitro but also with prog-
nosis.
Although multiple myeloma is charactensed by the pre-
sence of excess plasma cells in the bone marrow, the
identification of circulating isotypic lymphocytes (Ruiz-
Arguelles et al., 1984), as well as the production of colonies
in vitro consisting of cells which are lymphoplasmacytoid
(Millar et al., 1988), suggests that the major proliferative
compartment occurs in less differentiated B cells. Also, the
increased clonogenicity in vitro following cytotoxic
chemotherapy, despite a decrease in tumour burden, suggests
that multiple myeloma may be regulated by a homeostatic
control mechanism in vivo (Maitland et al., 1990). Further-
more, the failure to increase MY-CFUc formation in vitro by
the addition of cyclophosphamide or verapamil to the
VAMP regime (vincristine. adriamycin and methylpred-
nisolone) suggests that the potential increase in tumour pro-
liferative capacity after chemotherapy is dependent on the
nature of the cytotox.ic insult (Bell et al., 1990).
The concept that previous chemotherapy might influence
subsequent attempts to culture myeloma cells in vitro is likely
to produce constraints in addition to the possible require-
ment for added growth factors which may be required to
stimulate cell division. Mobilisation of putative precursors
which have evaded chemotherapy may be a prerequisite for
the successful culture of MY-CFUc in vitro in some in-
stances. Thus, in attempting to assess the relationship
between colony formation in vitro with genetic mutations, the
likelihood of a particular mutation effecting proliferation
may be influenced by the drugs to which the patient has been
subjected.
All eukaryotic organisms use GTP-binding proteins to con-
trol cellular processes which are involved in the transduction
of signals initiated by growth factors and lymphokines. ras is
a family of highly sequence-conserved proteins which have
functional similarities with other GTP-binding proteins. In
the human genome, three ras genes have been identified:
H-ras-l, K-ras-2 and N-ras (Ellis et al., 1981; Parada et al.,
1982; Hall et al., 1983). A similar mechanism has been
proposed for all GTP-binding proteins by which they exist in
two interconvertible forms. When bound to GDP they are
inactive, whereas they become functionally active when
bound to GTP. In addition, they can recycle from GDP to
GTP through intrinsic GTPase activity. Since activated ver-
sions of ras, in which mutations have led to the constitutive
production of the GTP-binding form, have been found in
many human solid tumours, including melanomas, teratocar-
cinomas, neuroblastomas and gliomas (for review see Bar-
bacid, 1986), it has been suggested that the abnormal growth
of some cancers is due to the continuous activation of the
signalling cascade initiated by the aberrant protein.
The role of mutated ras in haematological malignancies
remains controversial. In multiple myeloma, mutations have
been found in N-ras and K-ras, particularly at codon 61 in
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N-ras, with frequencies ranging from 12% to 47% of the
patient populations studied (Paquette et al., 1990; Matozaki
et al., 1991; Portier et al., 1992; Tanaka et al., 1992). In a
study by Neri et al. (1989) mutations in N-ras occurred in
only a fraction of the neoplastic clone, suggesting that they
may result from either the selective loss or the selective
acquisition of mutated alleles during tumour development. In
two other studies mutations in K- and N-ras occurred with
greater frequency in patients with fulminating disease (67%)
than in patients with less aggressive disease (27%) (Portier et
al., 1992; Corradini et al., 1993) suggesting that the develop-
ment of mutated ras alleles occurs in late or terminal stage
multiple myeloma. In none of these studies did the authors
attempt to culture cells which had mutated ras alleles in vitro.
Mutated H-ras has not been detected in clinical samples of
myeloma, although high levels of H-ras protein (p21) cor-
relate with poor prognosis (Tsuchiya et al., 1988). Also, the
greater expression of H-ras p21 in plasma cells from patients
with multiple myeloma rather than monoclonal gammopathy
of undetermined significance (MGUS) suggests that the
overexpression of H-ras proto-oncogene may be involved in
the transformation of the malignant plasma cell (Danova et
al., 1990).
The data presented represent a retrospective study of a
group of patients with multiple myeloma from whom mono-
nuclear cells were available which had been cryopreserved
from the same sample that was used for MY-CFUc. The aim
of the study was to determine whether patients from whom
MY-CFUc were cultured in vitro had a poorer prognosis
than those from whom cells did not proliferate in vitro and
whether colony formation in vitro was associated with detec-




Patients were recruited at random as they presented or were
undergoing treatment for multiple myeloma. All patients had
given written consent, following the Royal Marsden Hos-
pital's Ethics Committee approval, to take part in labora-
tory-based studies. The criterion for entering the study was
that sufficient mononuclear cells (MNCs) were available from
the same bone marrow aspirate, or one taken within 2
months of that used for colony growth, for isolation of DNA
for experiments involving the polymerase chain reaction
(PCR). Among these 13 patients from whom sequential sam-
ples were taken for PCR studies no further treatment had
occurred during the intervening period. There had been no
changes in haematological or clinical parameters during the
intervening period in these patients. Samples were accrued
during the period from September 1987 to March 1993 and
aliquots frozen as pellets in liquid nitrogen. The proliferation
of myeloma cells as colonies (MY-CFUc) was examined at
the time of bone marrow biopsy.
Bone marrow was aspirated from the posterior iliac crest
under local anaesthesia and heparinised as described pre-
viously (Millar et al., 1988). The biopsy sample from one
patient was taken from a pleural effusion.
Clinical status
A complete remission (CR) was defined as the absence of
measurable paraprotein and bone marrow infiltration by
myeloma cells of <5%. A partial response (PR) was defined
as a paraprotein level reduced by 50% and improvement in
all other clinical features sustained for greater than I month.
Clinical staging at the time of diagnosis was done according
to Durie and Salmon (1981).
Cell culture
Asynchronous cultures of RPMI-8226 and HL60 cell lines
were propagated by methods described previously (Millar et
al., 1988). Mononuclear cells were separated over Ficoll-
Hypaque (Boyum, 1968) and assayed for myeloma colonies
(MY-CFUc). Details of the methods have been reported
previously (Millar et al., 1988). Briefly, MY-CFUc were
assayed by plating 1 x 10' MNCs per plate using heavily
irradiated HL60 cells as an inhibiting layer to prevent the
proliferation of granulocyte-macrophage colonies (GM-
CFUc) (Montes Borinaga et al., 1990). Samples of MNCs
were also plated in the absence of an HL60 underlay. Over-
lays containing MNCs were added to underlays in either
0.5 ml of a-medium supplemented with 20% fetal calf serum
and 0.2% agar (final concentration) (agar/agar) or in 0.2 ml
of medium without agar (agar/liquid). All cultures were set
up in triplicate, incubated for 21 days at 37C in an atmos-
phere of 5% carbon dioxide, 10% oxygen and 85% nitrogen
and counted using an inverted microscope. Colonies con-
sisted of >50 cells. Cells from agar/liquid cultures were
harvested, stained for cytoplasmic immunoglobulins charac-
teristic of the patients' M protein using mouse anti-human
immunoglobulins conjugated to fluorescein isothiocyanate
(FITC) and examined by fluorescence microscopy. Colonies
were removed from agar/agar plates, collected by cytospin
(1500 r.p.m. for 5 min; Shandon, UK), stained with May-
Griinwald-Giemsa and examined microscopically. Plasma
cells were identified by strong cytoplasmic staining, the
presence of a perinuclear 'hor and an acentric nucleus or
nuclei.
Molecular studies
Polymerase chain reaction High molecular weight DNA was
extracted from aliquots of 5 x 106 MNCs, RPMI-8226 and
HL60 cells (Sambrook et al., 1989). The concentration of
DNA in the final solution was measured and used at a
concentration of 1 pg 100 ILI' reaction volume. Oligomer
primers for K-ras exons 1 and 2 were supplied by Orwell,
(Edinburgh, UK and biotinylated primers for N-ras exons 1
and 2 were synthesed in house (Dr H King, Chester Beatty
Laboratories, Institute of Cancer Research, London) (see
Table I).
The PCR reaction mixture consisted of 1 tg of DNA,
0.2mM each of dGTP, dTTP, dATP and dCTP (Perkin
Ehner, UK), 0.15 JLM each of the relevant upstream and
downstream primers, 2.5 units of Bio Taq, 1 x PCR buffer
and 4mM magnesium chloride (Bioline, London, UK). The
reaction volume was adjusted to 100yIL with dimethyl
pyrocarbonate (DEPC)-treated water. Samples were heated
at 94-C for 20 s followed by 35 cycles consisting of 94-C for
20 s, 55C for 30 s and 72-C for 30 s in a Hybaid Omnigene
(Hybaid, London, UK). DNA from RPMI-8226 and HL60
cells were used as controls. A 5 pl aliquot of the PCR
product was run on a 2% agarose minigel using HaeIII
fragments of 4p x 174 as reference standards (Gibco BRL,
UK). Purity of the PCR product was confirmed by the
presence of a single band between marker positions 118 and
194 bp.
Slot blottingfor ras mutations ras mutations were analysed
using the human ras Muta-lyser probe panels for K-ras
codons 12, 13 and 61 and for N-ras codons 12, 13 and 61.
The protocol for this was done according to the manufac-
turer's instructions (Clontech Labs., Cambridge Bioscewnce,
UK). Probes were end-labellW with [y- 3PJATP, as directed,
using T4 polynucleotide kinase.
To determine the sensitivity of the assay, DNA from
RPMI-8226 cells was mixed with placental DNA in known
amounts and subjected to PCR. The products were analysed
by Southern blotting.
Direct sequencing ofPCRproducts
K-ras exon I and exon 2 Aliquots of 50id1 of PCR products
were run on a 2% low melting point agarose gel (Ultrapure
or Nuseive, Gibco BRL, UK) for 1.5-2h at 140V. The
appropriate band was cut out from the gel and purified using
260MY-CFuc in absence of mutabd N- or K-a alieles
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Table I
Lpstream primer Downstream prirner
K-ras I 5'-CCT.GCT.GAA.AAT.GAC.TGA.AT 5'-TGT.TGG.ATC.ATA.TTFC.GTC.CA
K-ras 2 5'-CAG.ACT.GTG.TTT.CTC.CCT.TC 5'-TAA.ACC.CAC.CTA.TAA.TGG.TG
N-ras 1 5'-CTG.GTG.TGA.AAT.GAC.TGA.GT 5'-GGT.GGG.ATC.ATA.TTC.ATC.TA
N-ras 2 5'-GTT.ATA.GAT.GGT.GAA.ACC.TG 5'-ATA.CAC.AGA.GGA.AGC.CTT.CG
the 'Magic' PCR preparation DNA system (Promega Cor-
poration, USA). Purified PCR products were directly
sequenced using Sequenase 2.0 DNA sequencing kit (United
States Biochemicals. Cambridge Bioscience, UK) and incor-
poration of [3S1ATP. using the upstream primer for exon 2
of K-ras and the downstream primer for exon 1 of K-ras.
Samples were run on a 6% denaturing polyacrylamide gel.
dnred and exposed to Kodak X-OMAT for 20-44 h before
development.
N-ras exons I and 2 As purification of the PCR products
for N-ras exons 1 and 2 was impractical using the 'Magic'
PCR preparation system. the PCR mastermix was modified
to include a biotinylated upstream primer. The resulting
biotinylated PCR products were sequenced by separation on
a low melting point gel, the bands removed and melted at
65°C followed by incubation at 50°C with streptavidin-coated
Dynal beads (Dynal, UK) for 30 min with constant agitation.
The biotinylated PCR products attached to the beads were
removed by magnet and the supernatant discarded. The
beads were washed in 1 x Tris-boric acid-EDTA buffer
(TBE; Gibco BRL. UK) and re-extracted by magnet. The
resultant pure double-stranded DNA attached to the beads
was resuspended in 200 tLI of 0.15 m sodium hydroxide and
incubated for 5 min at room temperature. The beads were
reattached to the magnet and the supernatant discarded leav-
ing pure single-stranded DNA attached to the beads. Sequen-
cing was done using a Sequenase 2.0 kit (United States
Biochemicals) and incorporation of [32S1ATP using the down-
stream primers of both exons. After adding the stop solution.
the magnetic beads were removed from the assay mixtures by
magnet. Samples were run on a 6% denatunrng polyacryl-
amide gel and treated as above.
Results
Bone marrow aspirates were available from 45 patients. of
whom 43 had multiple myeloma (MM) and two had Walden-
str6m's macroglobulinaemia (W). A second biopsy was
available from three patients (two MM and one W), taken a
year (two MM patients) and 4 years (one W) after the first
sample. The stage at presentation, sex and isotype together
with the clinical status of each patient at the time when bone
marrow was available for study are shown in Table II. The
median time at which samples were received from the time of
diagnosis was 12 months (range 0-11 years 5 months). No
attempts were made to enrich MNCs for plasma cells since
this had not proved necessary in our previous studies on the
clonogenicity of myeloma cells in vitro (Millar et al., 1988).
Twenty-four samples from 45 patients produced MY-CFUc
which were confirmed by morphology and staining for the
light chain (Table III). In the majority of samples the
clonogenicity of the myeloma cell population ranged from
0.0057% to 0.093%, excepting that of MY-CFUc from
patients 16 and 18, who had progressive disease and in whom
it was higher, namely 1.0% and 0.3% respectively. At the
time of testing three patients were at presentation, six had
achieved PR, four were in CR after intensive therapy and 11
had progressive disease. SiJxteen of these patients had bone
marrow infiltration with plasma cells of at least 10% and
seven had an infiltration of 5% or less.
Preliminary experiments to optimise the conditions for
PCR were undertaken with the myeloma cell line RPMI-8226
(Matsuoko et al.. 1967) and the promyelocytic leukaemic line
HL60 (Collins et al.. 1977). DNA from these cell lines was





































subjected to PCR and examined by slot blotting with~P-
labelled probes and direct sequencing for mutations in K-ras
exons 1 and 2 and N-ras exons 1 and 2. In RPMI-8226 cells.
no mutations were detected in N-ras. A mutation was found
in K-ras exon 1, codon 12, in which GGT was replaced by
GCT (Figure 1). Onfly one allele was mutated. This is
different from the mutation reported previously (Neri et al..
1988). Since the RPMI-8226 cell line was established in 1967
(Matsuoko et al., 1967) culture conditions in different
laboratories may have enabled different subpopulations to
dominate the original parental cell line, or new mutations
may have arisen during the culture period in vitro, resulting
in no overt change of phenotype. Dilution experiments in
which placental DNA was mixed with DNA from RPMI-
8226 cells in known amounts and examined by slot blotting
after PCR showed that the mutated allele was detectable in
samples containing 10% RPMI-8226 DNA (Figure 2). This
sensitivity is similar to that noted by Farr et al. (1988) using
the HT 1080 cell line, which is heterozygous for N61 lysine.
In HL60 cells other workers (Bos et al., 1984) have shown
that there is a point mutation in N-ras codon 61 in which
CAA is replaced by CTA. Examination of PCR products by
slot blotting and direct sequencing confirmed this finding
(data not shown). No other mutations were found either in
K-ras exons 1 and 2 or in N-ras exon 1. Only one allele was
mutated.
In experiments with patients' samples, amplified PCR pro-
ducts of K- and N-ras from 48 samples of bone marrow and
one pleural effusion were subjected to hybridisation with
32P-labelled oligonucleotide probes and slot blotting. Samples
of RPMI-8226 and HL60 cells were included as controls for
mutations in K- and N-ras. No positive signals were detected
for mutated alleles in either K- or N-ras in any patient's
sample. Because mutations in myeloma cells have been
reported by other workers (Paquette et al., 1990; Matozaki et
al., 1991; Portier et al.. 1992; Tanaka et al., 1992), PCR
products from all samples in which background activity had
been detected by hybridisation and slot blotting were sub-
jected to direct sequencing. From the total of 288 slot blots,
18 samples were sequenced for N-ras exon 2. 13 for N-rasMYCFUc h asoe. o .itud N- or K-r Ades
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Table m Proliferation ofmyeloma (MY-CFUc) colonies in vitro
Patient Clinical Infiltration in MY-CFUc per Prolferationfrom Survivat
no. status BM (%) 10J MNCs Clonogenicity4 subsequent samples (months)
Ic.d PR 11 4 36 + 26*
2 PR 10 1 10 + 72
3d PD 35 2 5.7 - 15
4d PR 15 9 60 - 16
5d CR >10 3 30 + 73
6 PD >10 1 10 + 74
7cA CR 1 4 400 + 60*
8 PD <5 3 60 + 73
gd PD <5 1 20 - 8*
10 PR 30 280 930 + 62
11 PD 18 1 5.5 - 10*
12c PR <5 3 60 + 75
13d Presn. 50 2 40 + 3*
14 PR 5 4 80 + 75
15 Presn. 10 67 670 + 9*
16 PD 2 200 10 000 + 75*
17 d CR 5 24 480 + 4*
18d PD 10 300 3000 + 73
19 Presn. >10 4 40 + 76
20d PD 18 20 111 + 7*
21d PD 20 19 95 - 10*
22d CCR <5 13 260 + 22*
23 PD 47 84 178 + 6*
24 PD 50 110 550 + 5.5*
aNumber ofclonogenic cells per 106 plasma cells. 'Time between sample used for PCR studies and *death or until
present day (July 1994). Patients' samples subjected todirect sequencing ofPCR products shown at: 'forN-rasexon 1;
dfor N-ras exon 2.
G C A T A B C
GCT
Fuwe I Direct sequencing of amplified products of K-ras
codon 12 from the DNA of RPMI-8226 cells, showing the
deduced sequence of GCT (alanine) replacing GGT (glycine).
Sequencing was done from the 3'-primed end of the sequence.
Fge 2 Hybridisation of PP-labelled synthetic oligomer probes
of K-ras codon 12 to amplified PCR products of DNA from
RPMI-8226 cells. The concentrations of products from the cells
were 100%, 60%, 50%, 30%, 10%, 5%, 1%, 0.5%, 0.1%, 0.05%
and 0.0%. A, Arginine; B, alanine; C, glycine.MY-CFUc inabsence of mutated N- or K-rasalleles
BC Millar etal 0i
263
Table IV Current survival of patients examined for ras and clonogenicity in vitro
Patients whose cells gave MY-CFUc Patients who were negativefor MY-CFUc
No. of No. of
patients Median survival (range) patients Median survival (range)
13a 9 months (3-75 months) 1 la 14 months (1 -61 months)
IIlb 73 months (15-75 months) lob 16 months (15-75 months)
aDead. bAlive at July 1994.
exon 1 and five for K-ras exon 2. The samples which were
directly sequenced from patients whose mononuclear cells
had produced MY-CFUc in vitro are identified in Table III.
Wild-type alleles were found in all samples examined by
direct sequencing, but there were no mutated alleles.
The survival of patients used in this study is shown in
Table IV. Among patients who are alive and from whom
MY-CFUc were grown in vitro at the times when tests were
done for mutated N-or K-ras alleles, four have had no
further treatment. They remain in remission 62 (patient 10),
73 (patient 5), 74 (patient 6) and 75 months (patient 12) after
sampling. Six of the remaining patients received intensive
therapy with high-dose melphalan within 7 months after
samples were used in these studies, and one patient received
intensive therapy with busulphan 13 months after the sam-
ples were taken. Two of these seven patients now have
progressive disease 16 months and 73 months after samples
had been used for studies to detect mutated ras alleles.
Subsequent bone marrow aspirates from 19/24 of these
patients have produced myeloma colonies in vitro, including
nine patients who remain alive.
Among patients whose cells did not produce MY-CFUc in
vitro, ten remain alive, including the two patients with
Waldenstrom's macroglobulinaemia. In this group of patients
only one has had intensive therapy with high-dose melphalan
since the samples were used in vitro. Tumour cells from four
of these patients have subsequently produced myeloma col-
onies in vitro since this study, of whom one patient remains
alive.
Discussion
We have explored the possibility that patients from whom
MY-CFUc can be cultured have a poorer prognosis than
those whose tumour does not proliferate in vitro. We have
also investigated whether the detection of mutations in N-
and K-ras at exons I and 2 in bone marrow aspirates was
associated with our ability to grow MY-CFUc in vitro from
the same samples or one taken within 2 months of that
assessed for colony formation. Studies to detect activated
oncogenes or quantitate the expression of specific proto-
oncogenes in multiple myeloma may provide information
about the pathogenesis of the disease and may provide
targets for new treatment strategies if they are associated
with poor prognosis. Despite the low levels of plasma cells in
eight samples, MY-CFUc were grown from 24 samples from
45 patients, including those that had infiltration with plasma
cells of 5% or less, and included four patients who were in
complete response at the time of testing. We have previously
shown that in patients who respond to induction
chemotherapy with VAMP the residual myeloma cell popula-
tion has enhanced proliferative activity in vitro, suggesting
that tumour growth is regulated by a homeostatic control
mechanism(s) (Maitland et al., 1990) which may be
modulated by specific treatment regimens (Bell et al., 1990).
Furthermore, the median time to clinical CR is less than
required for the disappearance of MY-CFUc from their bone
marrow (Maitland et al., 1990) or for the detection of the
malignant clone by molecular techniques (Bird et al., 1993).
Among these patients, the four who were in CR at the time
of testing had had treatment with high-dose melphalan 25
months (patient 5), 27 months (patient 7), 1 month (patient
17) and 4 months (patient 22) previously. Patient 17 was
diagnosed as having progressive disease 7 weeks after the
samples were taken for in vitro studies. However, it may be
too simplistic to suggest that the production of MY-CFUc in
vitro was due to clonal activation in this instance since a
second patient (no. 5) has remained in CR for 73 months
without further treatment even though MY-CFUc have been
grown in vitro on four subsequent occasions. This observa-
tion is not an isolated instance (BC Millar and JBG Bell,
unpublished observations). It suggests that immune modula-
tion in vivo may also contribute to the suppression of tumour
cell proliferation and that in some instances this growth-
inhibitory effect is absent in vitro.
In no instance was mutated N- or K-ras detected from
either samples which produced colonies in vitro or those that
did not. While the failure to detect mutated ras alleles in
samples which had 5% or less infiltration with plasma cells
but which produced MY-CFUc in vitro is likely to be due to
the sensitivity of the assay, this must be assessed in relation
to the clonogenicity of the myeloma cell population from
individual patients. Since a single mutated allele in a mixed
population was not detectable below the level of 10% (also
reported by Farr et al., 1988), the possibility that cells which
are clonogenic in vitro carry a mutation in N- or K-ras
cannot be excluded. However, such a proposal suggests that
cells which may have a mutation represent less than 0.1% of
the tumour burden in most instances. This level of mutation
would not have been detectable in most instances in purified
populations of plasma cells given the level of tumour
infiltration in the samples and the clonogenicity of the cells.
Also, since cells other than identifiable plasma cells may be
part of the malignant clone, purification of the plasma cell
compartment could remove putative clonogenic cells, which
may be capable of both proliferation and differentiation in
vitro. While examination of individual colonies would resolve
the possibility that some cells which are clonogenic in vitro
carry a mutated ras allele, the data (Table III) suggest that
they would represent a minor contribution to the tumour
burden in vivo.
Furthermore, since MY-CFUc have been grown from sub-
sequent bone marrow aspirates from 19/24 patients whose
tumour proliferated in vitro in the initial scan, including 9/11
who remain alive, the data suggest that even if occult muta-
tions in N- or K-ras had effected proliferation in vitro they
did not contribute to resistance to chemotherapy or effect
early relapse or survival. Also the observation that samples
from four patients whose tumour did not produce MY-CFUc
in vitro in the initial assay yielded MY-CFUc on subsequent
occasions could indicate the development of additional
genetic changes, clonal activation, the absence of in vivo
inhibitory constraints or merely differences in the quality of
putative progenitor cells in the bone marrow aspirates.
In other haematological malignancies, the role of mutated
ras remains controversial. Although mutations have been
found in patients with leukaemias, there was no correlation
between the presence of mutations and cytological features or
immune phenotype (Ahuya et al., 1990). Also, in patients
with acute myelogenous leukaemia (AML) ras mutations
were not detected in four patients in relapse even though they
had been detected at presentation (Farr et al., 1988), suggest-
ing that ras mutations arise as part of the oncogenic process
but may be subsequently lost as other mutations occur within
the malignant clone. In AML, even in situations in which
mutations in N-ras were detected in primary colonies in vitro,
their expression was heterogeneous (Bashey et al., 1992),MY-cFuc in absmne of mutaed N- or K-es akes
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suggesting that the expression of this oncogene had occurred
after the initial development of malignancy. The authors
made no comment regarding the potential proliferative
advantage that such mutations might elicit in the tumour cell
population in vivo. This caution is justifiable since, unless
mutated alleles are present throughout the tumour, it is
difficult to determine whether mutations in a subpopulation
cultured in vitro reflect enhanced growth potential in vivo. In
B-cell dyscrasias there is evidence that the involvement of
oncogene expression in the malignant phenotype is dependent
on the stage of differentiation. In acute lymphocytic leu-
kaemia. 10-20% of patients have been reported to have
point mutations in ras oncogenes (Neri et al., 1988), whereas
mutations in ras have not been detected in patients with
non-Hodgkin's lymphoma or chronic lymphocytic leukaemia
(Neri et al., 1988; Selvanayagam et al., 1988).
Our data suggest that mutated N- or K-ras alleles are
unlikely to be of clinical importance in multiple myeloma as
is the case with non-Hodgkin's lymphoma and chronic lym-
phocytic leukaemia. Our ability to culture the tumour in vitro
independently of the disease status or prognosis of individual
patients suggests that immunoregulatory mechanisms contri-
bute to tumour control in vivo, and genetic changes in some
individuals may necessitate the provision of additional
growth factors in vitro, as has been reported by other
workers (Kawano et al.. 1988).
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